Table 2.

Endometrial hyperplasia incidence and immunohistochemical expression of phosphorylated S6 ribosomal protein and serine-phosphorylated IRS-1 in vehicle- and WAY-129327–treated Eker (Tsc2+/−) rat endometrium

TreatmentNo. of hyperplastic foci/no. uterine cross-sections% Hyperplastic foci (+) for phospho-(S235) S6% Hyperplastic foci (+) for phospho-(S636/639) IRS-1
Vehicle 12 of 21000
Vehicle 21 of 11000
Vehicle 31 of 81000
Vehicle 47 of 101000
Vehicle 56 of 121000
Vehicle 65 of 61000
Vehicle 73 of 121000
Vehicle 88 of 91000
Vehicle 93 of 101000
Vehicle 108 of 91000
Vehicle 1110 of 101000
Total54 of 89 (61%)
WAY-129327 11 of 800
WAY-129327 21 of 1100
WAY-129327 31 of 1000
WAY-129327 40 of 15N/A*N/A*
WAY-129327 50 of 11N/A*N/A*
WAY-129327 60 of 11N/A*N/A*
WAY-129327 70 of 13N/A*N/A*
WAY-129327 83 of 11030
Total6 of 90 (7%)
P<0.001<0.001NS

NOTE: All rat endometrial sections expressed IRS-1 and/or IRS-2.

Abbreviation: NS, not significant.

  • *Not applicable due to lack of endometrial hyperplasia.

  • Statistical significance was evaluated between the vehicle- and WAY-129327–treated groups by χ2 analysis.